First chronic platelet glycoprotein IIb/IIIa integrin blockade: A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions

Circulation

Volumn 96, Issue 1, 1997, Pages 76-81

  Simpfendorfer, Conrad ^a   Kottke Marchant, Kandice ^a   Lowrie, Marsha ^c   Anders, Robert J ^b   Burns, Daniel M ^b   Miller, Dave P ^a   Cove, Christopher S ^c   DeFranco, Anthony C ^c   Ellis, Stephen G ^c   Moliterno, David J ^c   Raymond, Russell E ^c   Sutton, Joseph M ^c   Topol, Eric J ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c NONE

Author keywords

Angina; Drugs; Glycoproteins; Platelet aggregation inhibitors; Platelets; Revascularization

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; COLLAGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEMOGLOBIN; HEPARIN; RISTOCETIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; WARFARIN; XEMILOFIBAN;

ADULT; AGED; ARTICLE; ATHERECTOMY; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART MUSCLE REVASCULARIZATION; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

EID: 0030754004     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.1.76     Document Type: Article

References (23)

1. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;381: 1714-1719.
2. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332: 1553-1559.
3. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2373-2380.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
5. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BD, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
6. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995;74:302-308.
7. Coutre S, Leung L. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Annu Rev Med. 1995;46: 257-265.
8. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Markis JE, Pratt DM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH, for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med. 1991;115:256-265.
9. Horrigan MCG, Tcheng JE, Califf RM, Kitt M, Lorenz T, Sigmon K, Lincoff AM, Topol EJ, for the IMPACT-II Investigators. Maximal benefit of integrelin platelet IIb/IIIa blockage 6-24 hours after therapy: results of the IMPACT-II trial. J Am Coll Cardiol 1996;27(suppl A):55A. Abstract.
10. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur Heart J. 1995;16(suppl L):11-15.
11. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Szalony JA Haas NF, King LW, Zablocki JA, Keller BT, Broschat K, Engleman VW, Herin M, Jacmin P, Feigen LP. SC-54684A: an orally active inhibitor of platelet aggregation. Circulation. 1995;91: 403-410.
12. Szalony JA, Haas NF, Salyers AK, Taite BB, Nicholson NS, Mehrotra DV, Feigen LP. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. Circulation. 1995;91:411-416.
13. Anders RJ, Alexander JC, Hantsbarger GL, Burns DM, Oliver SD, Cole G, Fitzgerald DJ. Demonstration of potent inhibition of platelet aggregation with an orally active GPIIb/IIIa receptor antagonist. J Am Coll Cardiol. 1995;(special issue):117A. Abstract.
14. Frederick LG, Suleymanov OD, King LW, Salyers AK, Nicholson NS, Feigen LP. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. Circulation. 1996;93:129-134.
15. Narjes H, Weisenberger H, Muller TH, Deichsel G, Krause J. Tolerability and platelet fibrinogen receptor occupancy after oral treatment with BIBU 104XX in healthy volunteers. Thromb Haemost. 1995;73:1315. Abstract.
16. Cook NS, Bruttger O, Pally C, Hagenbach A. The effects of two synthetic glycoprotein IIb/IIIa antagonists, RO 43-8857 and 1-700,462, on platelet aggregation and bleeding in guinea pigs and dogs: evidence that RO 43-8857 is orally active. Thromb Haemost. 1993;70:838-847.
17. Cook NS, Kottirsch G, Zerwes HG. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future. 1994;19:135-159.
18. Mousa SA, De Grado WF, Mu D-X, Kapil RP, Lucchesi BR, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Circulation. 1996;93: 537-543.
19. Moliterno DJ, Califf RM, Anderson K, Weisman HF, Topol EJ, EPIC Study Investigators. Special considerations for diabetics receiving platelet IIb/IIIa antagonists during coronary interventions: results from the EPIC Trial. J Am Coll Cardiol. 1995; 23:155A. Abstract.
20. Lincoff AM, Tcheng JE, Bass TA, Popma JJ, Teirstcin PS, Kleiman NS, Weisman HF, Musco MH, Cabot CF, Berdan LG, Califf RM, Topol EJ, Prolog Investigators. A multicenter randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GPIIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization. J Am Coll Cardiol. 1995;25:80A. Abstract.
21. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing coronary intervention. Circulation. 1995;91:2882-2890.
22. Boehrer JD, Kereiakis DJ, Navetta FJ, Califf RM, Topol EJ, for the EPIC Investigators. Effect of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol. 1994;74:1166-1170.
23. Harrington RA, Kleinman NS, Kottke-Marchant K, Lincoff M, Tcheng JE, Sigmon KN, Joseph D, Rio G, Trainor K, Rose D, Greenberg CG, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995;76:1222-1227.